Tempus AI shares leap on forecast-beating results, revenue guidance

Tempus AI (TEM) surged 9% in premarket trading after reporting robust second-quarter results that surpassed analyst expectations, with a narrower loss per share of $0.22 and revenue of $314.6 million, exceeding the $297.8 million consensus. The genetic testing firm demonstrated strong operational momentum, including a 115.3% year-over-year increase in genomics revenue and a 30% rise in clinical volumes, prompting management to raise its full-year 2025 revenue forecast to $1.26 billion and project a positive Adjusted EBITDA of $5 million, indicating an improved financial outlook.

Analysis

Tempus AI (TEM) delivered a robust second-quarter performance, significantly surpassing analyst expectations and signaling strong operational momentum. The company reported revenue of $314.6 million, beating the $297.8 million consensus, and a narrower-than-expected loss per share of $0.22 versus a $0.25 forecast, which triggered a 9% premarket share price increase. Growth was primarily fueled by the Genomics segment, where revenue surged 115.3% year-over-year to $241.8 million, driven by a 30% re-acceleration in clinical volumes for its NGS tests. This includes notable volume growth in both Oncology (up 26%) and Hereditary testing (up 32%). The Data and Services segment also posted a healthy 35.7% revenue increase, underscoring the value of its data licensing business. Critically, management raised its full-year 2025 revenue guidance to $1.26 billion and projected a positive adjusted EBITDA of $5 million for the year. This forecast represents an approximate $110 million improvement from 2024 and marks a pivotal potential inflection point toward profitability.

Key Decisions for Investors

• Investors should view the combination of a top-and-bottom-line beat, accelerating clinical volumes, and upwardly revised guidance as strong validation of the company's growth strategy and market execution.
• The projection of a positive adjusted EBITDA of $5 million for full-year 2025 is a key catalyst; continued progress toward this profitability milestone in subsequent quarters will be a critical performance indicator to monitor.
• Given the significant revenue acceleration in the Genomics segment, it is prudent to assess the sustainability of this growth rate and the company's ability to continue improving margins as it scales operations.